Related references
Note: Only part of the references are listed.Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
Francesca Guidetti et al.
JOURNAL OF CLINICAL MEDICINE (2023)
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma
Baptiste Eluard et al.
BLOOD (2022)
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2022)
Kinase inhibition in autoimmunity and inflammation
Ali A. Zarrin et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers
Jacob J. Adashek et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma
Yun Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies
Venkateshwar Rao Gummadi et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
Vanessa E. Kennedy et al.
FRONTIERS IN ONCOLOGY (2020)
Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)
William T. McElroy
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors
Marian C. Bryan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Overcoming adaptive therapy resistance in AML by targeting immune response pathways
Katelyn Melgar et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment -Based Drug Design
Katherine L. Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors
Jennifer Hanisak et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome
Jordina Rovira et al.
CLINICAL CANCER RESEARCH (2016)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin
Ting Peng et al.
ACTA PHARMACOLOGICA SINICA (2014)
MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma
C. Fernandez-Rodriguez et al.
LEUKEMIA (2014)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2009)
Crystal structures of IRAK-4 kinase in complex with inhibitors: A serine/threonine kinase with tyrosine as a gatekeeper
Zhulun Wang et al.
STRUCTURE (2006)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
